These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

71 related items for PubMed ID: 16801577

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study.
    Hedblad B, Zambanini A, Nilsson P, Janzon L, Berglund G.
    J Intern Med; 2007 Mar; 261(3):293-305. PubMed ID: 17305652
    [Abstract] [Full Text] [Related]

  • 3. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial.
    Caballero AE, Saouaf R, Lim SC, Hamdy O, Abou-Elenin K, O'Connor C, Logerfo FW, Horton ES, Veves A.
    Metabolism; 2003 Feb; 52(2):173-80. PubMed ID: 12601628
    [Abstract] [Full Text] [Related]

  • 4. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
    Yu J, Jin N, Wang G, Zhang F, Mao J, Wang X.
    Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Long-term cardiovascular effects of insulin sensitizer troglitazone on non-diabetic individuals with insulin resistance: double blind, prospective randomized study.
    Stakos DA, Schuster DP, Sparks EA, Wooley CF, Osei K, Boudoulas H.
    J Cardiol; 2003 Apr; 41(4):183-90. PubMed ID: 12728539
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P, Sitagliptin Study 019 Group.
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [Abstract] [Full Text] [Related]

  • 8. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.
    Sorrentino SA, Bahlmann FH, Besler C, Müller M, Schulz S, Kirchhoff N, Doerries C, Horváth T, Limbourg A, Limbourg F, Fliser D, Haller H, Drexler H, Landmesser U.
    Circulation; 2007 Jul 10; 116(2):163-73. PubMed ID: 17592079
    [Abstract] [Full Text] [Related]

  • 9. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
    Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Gravina A, Fogari E, Maffioli P, Cicero AF.
    Metabolism; 2008 Nov 10; 57(11):1552-7. PubMed ID: 18940393
    [Abstract] [Full Text] [Related]

  • 10. Effects of rosiglitazone on body fat distribution and insulin sensitivity in Korean type 2 diabetes mellitus patients.
    Hwang YC, Lee EY, Lee WJ, Cha BS, Yoon KH, Park KS, Lee MK.
    Metabolism; 2008 Apr 10; 57(4):479-87. PubMed ID: 18328348
    [Abstract] [Full Text] [Related]

  • 11. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes.
    Stocker DJ, Taylor AJ, Langley RW, Jezior MR, Vigersky RA.
    Am Heart J; 2007 Mar 10; 153(3):445.e1-6. PubMed ID: 17307426
    [Abstract] [Full Text] [Related]

  • 12. Glucose turnover and intima media thickness of internal carotid artery in type 2 diabetes offspring.
    Anderwald C, Pfeiler G, Nowotny P, Anderwald-Stadler M, Krebs M, Bischof MG, Kozakova M, Luger A, Pacini G, Roden M, Waldhäusl W.
    Eur J Clin Invest; 2008 Apr 10; 38(4):227-37. PubMed ID: 18339003
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effect of thiazolidinedione treatment on progression of subclinical atherosclerosis in premenopausal women at high risk for type 2 diabetes.
    Xiang AH, Peters RK, Kjos SL, Ochoa C, Marroquin A, Goico J, Tan S, Wang C, Azen SP, Liu CR, Liu CH, Hodis HN, Buchanan TA.
    J Clin Endocrinol Metab; 2005 Apr 10; 90(4):1986-91. PubMed ID: 15623809
    [Abstract] [Full Text] [Related]

  • 17. Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial.
    Dashora UK, Sibal L, Ashwell SG, Home PD.
    Diabet Med; 2007 Apr 10; 24(4):344-9. PubMed ID: 17298589
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.